SHTG Daily Digest — Weiss Lab

A thin cycle on both fronts — no new top-tier lipid papers after dedup, so this episode leans on two next-tier LPL papers (one showing FCS patients from Ionis' Balance trial carry less Lp(a) than genetics would predict), and the trade press had no new SHTG, Arrowhead, Alnylam or Ionis stories in the last five days.

A thin cycle on both fronts — the only top-tier lipid paper is the NEJM letter showing one-year durability of CTX310, CRISPR Therapeutics' one-time ANGPTL3 knockout, and the trade press ran no new SHTG, Arrowhead, Alnylam or Ionis stories in the five-day window.

A thin cycle on both sides: no top-tier lipid papers, but the next tier brought a network meta-analysis finding that faster triglyceride lowering in HTG pancreatitis has not been shown to improve hard outcomes, a large CT-plus-triglyceride model for predicting severe HTG pancreatitis, and a case series on plasma infusion for infantile ApoC-II deficiency; on the industry side there was no new SHTG,...

Another thin cycle: no top-tier lipid papers, but the next tier brought a high-specificity Cas12a editing study that knocked out Angptl3 in mice and a 526-patient study showing that how fast triglycerides fall after admission predicts severity in hypertriglyceridemic pancreatitis; on the industry side there was no new SHTG news, and the only fresh item was a second Ionis-partnered Phase 3 win of t...

A thin cycle on both fronts — the lipid literature offered only next-tier work (an ANGPTL3 base-editing delivery study, an APOC3 variant association in Indian MASLD, and two clinical-care papers on hypertriglyceridemia), and the industry side produced no new SHTG news, with the only fresh item being Ionis's partnered antisense drug sefaxersen hitting its Phase 3 interim endpoint in IgA nephropathy...

It's a thin cycle on both fronts — the only notable lipid-biology paper this week is a new CRISPR rabbit model of APOA5-driven hypertriglyceridemia, and the SHTG-relevant industry press was quiet, with searches turning up only stories already covered in recent episodes.

A quiet cycle on both fronts — the lipid literature offered only next-tier evidence (CRISPR/base-editing for ANGPTL3, plasma exchange for SHTG crises, and an erythritol-apoC-III diet link), and the industry side had no new Arrowhead/Alnylam/Ionis news beyond last cycle's already-covered Novartis/Ionis pelacarsen failure.

A new JACC: Basic to Translational Science analysis shows ApoC-III inhibition with olezarsen strips triglycerides and cholesterol out of Lp(a) particles without lowering Lp(a) mass itself, while two case reports underline how hard SHTG still is to diagnose and treat at the bedside — and it was a quiet week for Arrowhead, Alnylam, and Ionis in the trade press.

A quiet cycle on both fronts — PubMed's top-tier journals produced zero SHTG/ANGPTL/APOC3/LPL hits this week (next-best-tier picks below cover ANGPTL3 inhibition, lipodystrophy genetics, and LPL biochemistry), and none of the tracked trade outlets published fresh news on SHTG, Arrowhead, Alnylam, or Ionis in the last five days.

No top-tier journal papers cleared the bar this cycle, but next-tier literature offered genetics-to-therapy signal on FCS (a novel APOA5 variant and an ApoC-II case series) alongside two olezarsen/zodasiran commentary pieces, while the industry side was quiet — everything found in the 5-day window on Arrowhead, Alnylam, or Ionis's lipid programs had already been covered in the prior cycle.

It's a quiet cycle on both fronts — no top-tier-journal lipid papers cleared the bar, but the biggest industry story is a jolt: Novartis and Ionis's Lp(a)-lowering drug pelacarsen just failed its pivotal cardiovascular outcomes trial, raising hard questions for the whole class of RNA-targeting lipid therapies (including the APOC3/ANGPTL3 programs this show tracks).

A quiet cycle on both fronts — no top-tier lipid papers cleared the bar in PubMed this week, and no genuinely new SHTG/Arrowhead/Alnylam/Ionis industry stories broke in the last 5 days beyond what's already been covered (Tryngolza's sHTG approval and Arrowhead's ESC '26 plozasiran data remain the dominant recent storylines).

This is a quiet, largely repeat cycle — the CTX310 (ANGPTL3 base-editing) durability letter and the Arrowhead-vs-Ionis ESC Congress safety showdown that drove the last digest remain the dominant SHTG stories, with nothing genuinely new clearing the bar on either the science or industry side since two days ago.

ESC Congress in Munich delivered the payoff this cycle predicted last time — CRISPR Therapeutics published one-year durability data for its ANGPTL3 base-editing candidate CTX310 in NEJM, while Arrowhead used the same meeting to lay out a case that plozasiran (Redemplo) is at least as good as, and possibly safer than, Ionis's Tryngolza in severe hypertriglyceridemia.

No new top-tier lipid papers broke this cycle, but a strong human ANGPTL3-deficiency kinetics study and a novel TREM2–APOC3 mechanism paper stood out on the science side, while the industry side was quiet on new sHTG-specific news in the last five days — the main thing to watch is ESC Congress in Munich, though this year it's Alnylam's amyloid-cardiomyopathy franchise, not its lipid pipeline, in t...

No top-tier-journal SHTG papers landed this cycle, but a broadened PubMed pull surfaced two drug-focused reviews on plozasiran and olezarsen plus a Korean GWAS turning up a novel ANGPTL3 variant, while the industry side stayed quiet with nothing new in the 5-day window from Ionis, Arrowhead, or Alnylam.

No top-tier journal papers on SHTG/ANGPTL/APOC3/LPL cleared the bar this cycle (next-best-tier picks below on ANGPTL3 inhibition and APOC3-targeted siRNA are still worth a read), and it's a quiet week for Arrowhead/Alnylam/Ionis press coverage ahead of the SHASTA-3/4 late-breaker at ESC on August 30.

No top-tier trial readouts this cycle, but the science side keeps chipping at the APOC3/ANGPTL3/ANGPTL4/LPL mechanism (postprandial handling, CKD dyslipidemia, pancreatitis risk prediction) while the industry side remains anchored by Arrowhead's positive plozasiran Phase 3 data, with the full readout due at ESC on August 30.

A quiet cycle on both fronts — the only qualifying PubMed hit is a JAMA news synopsis recapping June's Tryngolza approval rather than new primary research, and no fresh trade-press stories on SHTG, Arrowhead, Alnylam, or Ionis cleared the 5-day/dedup bar, with the field's most consequential items (Arrowhead's SHASTA-3/4 topline and Alnylam's Amvuttra-driven selloff) already covered in a recent epi...

No new top-tier journal papers this cycle — the science side is quiet reviews and case reports on the APOC3/LPL axis — while on the industry side Arrowhead bought itself a priority review voucher to speed its plozasiran (Redemplo) filing in severe hypertriglyceridemia, sharpening its race against Ionis's newly-expanded Tryngolza.

A quiet cycle on both fronts — one non-top-tier observational paper on pancreatitis recurrence in hypertriglyceridemia, and no fresh industry news beyond what's already been covered (Arrowhead's SHASTA-3/4 phase 3 data and the Ionis/Alnylam earnings stories all fell in prior episodes' windows).

A genuinely quiet cycle — the only new lipid-biology paper worth flagging is a human physiology study nailing down how ANGPTL3 deficiency reshapes triglyceride-rich lipoprotein clearance, while the industry side produced no fresh, previously-uncovered news on Arrowhead, Alnylam, or Ionis in the last five days.

It was a quiet week for new top-tier SHTG/ANGPTL/APOC3/LPL science, but Alnylam's 30% stock plunge on a surprise Amvuttra guidance cut is a reminder of how quickly sentiment can turn on RNAi-platform companies even as their lipid-focused programs (and rivals Ionis and Arrowhead) keep advancing on separate tracks.

It's a quiet cycle on both fronts — no new top-tier lipid papers cleared the bar, and the only notable industry item is a STAT News recap of the Arrowhead–Ionis triglyceride-drug rivalry that surfaces a previously undisclosed detail: Ionis's patent-infringement allegation against Arrowhead over the RNAi technology behind Redemplo (plozasiran).

A quiet cycle for new peer-reviewed lipid literature was overshadowed by Arrowhead Pharmaceuticals' Phase 3 plozasiran data in severe hypertriglyceridemia, which analysts are calling a "best-case scenario" that puts the drug on a collision course with Ionis's Tryngolza.